Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Rapid Nutrition PLC (ALRPD.PA)
Mildenhall, GB
Rapid Nutrition PLC is a natural healthcare enterprise that researches, develops, and manufactures a diverse portfolio of science-backed health and wellness products. Its market presence extends across the United Kingdom, Australia, Asia, the United States, and other international regions. The company offers a range of organic and natural, scientifically formulated health food supplements, primarily distributed under the SystemLS and Leisa's Secret trademarks. Furthermore, it produces oral antiviral therapeutic solutions, marketed as Azurene, aimed at combating influenza and the common cold. The company was established in 2001 and is headquartered in London, UK.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-04 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%-44.6% Q2'25: -52.4% (vs Q1'24)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+100.0% ★ Q2'25: +100.0% (vs Q1'24)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%-328.3% Q2'25: -1,708.7% (vs Q1'24)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%-167.1% Q2'25: -1,032.2% (vs Q1'24)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%-410.1% Q2'25: -582.4% (vs Q1'24)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+159.8% Q2'25: +2.1% (vs Q1'24)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×-0.06× Q2'25: -0.02× (vs Q1'24)
| Metric |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. |
|---|---|---|---|
| Revenue |
917.0K
est: 2.99M (-69.3%)
|
3.47M
est.
|
3.89M
3.89M – 3.89M
+12.3% YoY
|
| EBITDA |
-1.52M
est: -1.73M (+12.1%)
|
-2.00M
est.
|
-2.25M
-2.25M – -2.25M
-12.3% YoY
|
| EBIT |
-1.53M
est: -1.79M (+14.6%)
|
-2.08M
est.
|
-2.33M
-2.33M – -2.33M
-12.3% YoY
|
| Net Income |
-2.90M
|
—
est.
|
—
— – —
|
| SGA |
2.01M
est: 3.74M (-46.1%)
|
4.33M
est.
|
4.86M
4.86M – 4.86M
+12.3% YoY
|
| EPS |
0.00
|
—
est.
|
—
— – —
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Simon Ledger | Executive Chairman, Chief Executive Officer & MD | 174.3K | male |
| Michael Zhu | Chief Financial Officer | 34.0K | male |
| John E. Lewis | Scientific Director | — | — |
| Ruth Kendon | Head of Research & Product Development | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ALRPD.PA
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
